Dr. Singhvi will provide an overview of the company's strategy, research
and development progress and strategic partnerships. A link to an audio
webcast of this presentation will be available through the company's website,
http://www.novavax.com after the event and will remain on the Novavax website
for 30 days.

ABOUT NOVAVAX

Novavax Inc. is committed to leading the global fight against infectious
disease by creating novel, highly potent vaccines that are safer and more
effective than current preventive options. Using the company's proprietary
virus-like particle (VLP) and Novasome(R) adjuvant technologies, Novavax is
developing vaccines to protect against H5N1 pandemic influenza, seasonal flu
and other viral diseases. Novavax's particulate vaccines closely match
disease-causing viruses while lacking the genetic material to cause disease,
which provides potential for greater immune protection at lower doses than
current vaccines. With an exclusive portable manufacturing system that allows
for rapid mass-production of vaccines, Novavax is uniquely positioned to meet
global public health needs.